Altimmune, Inc. today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc., (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.
Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update.
Conference Call Information:
| Date: | Wednesday, November 10 |
| Time: | 8:30 am Eastern Time |
| Domestic Dial-in: | (844) 615-6509 |
| International Dial-in: | (918) 922-3148 |
| Conference ID: | 5783655 |
| Webcast: | https://edge.media-server.com/mmc/p/zgrrmubx |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor and Media Contact:
Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com
